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Introduction
•

•

•

•

Heart failure with preserved ejection
fraction (HFpEF), formerly known as
diastolic heart failure, is a diagnosis that
is becoming more prevalent as the
population ages. HFpEF affects 10 in
every 1,000 individuals over 65 years of
age, with 870,000 new cases being
diagnosed every year (Tawil & Gelzinis,
2016).
HFpEF accounts for 54% of all heart
failure diagnoses. The five year
mortality for patients with HFpEF is
42.3% (Singh & Mehta, 2018).
HFpEF is a clinical syndrome that
encompasses several cardiovascular
disease processes and symptoms that
relate to diastolic dysfunction while
retaining a left ventricular ejection
fraction (LVEF) of > 50% (Harper, Patel,
& Lyon (2018).
HFpEF requires careful consideration of
the healthcare provider when exploring
clinical decisions relating to the
management of the disease and
beyond.

Topic Importance
•

•

•

•

As the population ages, HFpEF is
becoming more prevalent. It is the
leading cause of hospitalization in
patients 65 and older (Tawil & Gelzinis,
2016).
The management of HFpEF creates
unique challenges for the anesthesia
provider and intraoperative clinical
management and decision making, and
the disease is associated with increased
mortality postoperatively (Singh &
Mehta, 2018).
Health care expenses related to heart
failure totaled $30 billion in 2013
(Gazewood & Turner, 2017).
In the next 20 years the prevalence of
heart failure is projected to increase by
50% (Farris et al., 2017).

Underlying Pathophysiology

Disease Process
•

•
•
•

•

•

HFpEF consists of a combination of cardiovascular disease processes that become
prevalent in advanced age. As the patient ages, the cardiomyocyte function
degrades, and the production and utilization of ATP decreases cause the inability of
the ventricles to relax as well as stiffness resulting in issues with ventricular
compliance and filling (Singh & Mehta, 2018).
As the heart works to maintain the same contractility to deliver oxygen to the
tissues, the walls may hypertrophy to elicit a greater pressure gradient and
overcome the cardiac wall stiffness and impair relaxation (Farris et al., 2017).
As the heart continues to fail, symptoms of HFpEF may arise, such as fatigue,
dyspnea on exertion, and edema (Gazewood & Turner, 2017).
On the onset of symptoms, the patient may seek treatment. The diagnosis of
HFpEF consists of the presence of signs and symptoms of heart failure, and
echocardiogram confirming LVEF > 50%, and a beta-natriuretic peptide (BNP) of >
100 pg/mL (Tawil & Gelzinis, 2016).
Because the pathophysiology of HFpEF is irreversible, there is no treatment
available. However, the symptoms of HFpEF can be managed with diet and lifestyle
changes, as well as medications such as diuretics to reduce preload, beta blockers
to reduce afterload, and ACE inhibitors to prevent further remodeling of the
myocardial tissue (Harper et al., 2017).
HFpEF is a chronic disease that when diagnosed will be present for the remainder
of the patient’s lifetime.

Signs and Symptoms
•
General fatigue and weakness
•
Dyspnea, paroxysmal nocturnal dyspnea, or orthopnea
•
Edema
•
Jugular venous distension
•
S3 heart sound
•
Displaced apical impulse
(Gazewood & Turner, 2017)

•

•
•

•

•

Implications for
Nursing Care
•
•

•

•

The management of HFpEF requires
diet and lifestyle changes, as well
has a strict medication regimen.
The nurse has an important role in
the education of the HFpEF patient
on these expectations for
prevention of clinical deterioration
and an acute on chronic
exacerbation (Cavalcanti & Pereira,
2014).
Patients that develop an acute on
chronic exacerbation of HFpEF may
be admitted to inpatient units. In
this case, the nurse must be aware
that the patient could exhibit
exercise intolerance and shortness
of breath. This may impede nursing
care and require management in an
acute care setting (Gazewood &
Turner, 2017).
HFpEF presents challenges to the
anesthesia provider, as it causes a
reduction in cardiac output which
can be amplified by anesthetic
agents (Singh & Mehta, 2018).

Conclusion
•

•

•

•

HFpEF is a complex medical
syndrome that affects a significant
portion of the population and poses
many unique clinical considerations
for the healthcare provider.
It is important for healthcare
providers to be aware of the
pathophysiology and considerations
related to HFpEF in order to make
evidence-based decisions involving
the care of patients who present
with the disease.
As the population ages, the
prevalence of HFpEF is increasing
significantly (Tawil & Gelzinis,
2016).
Although treatment for HFpEF does
not exist, symptoms can be
managed with medication and
lifestyle changes. The nurse is in a
unique position to provide
education to the HFpEF patient to
improve quality of life (Cavalcanti &
Pereira, 2014).

•

•

Figure 1. Specific biological phenotypes in HFpEF (Lewis et al., 2017).

•

As the ventricle hypertrophies and becomes stiff, the cardiac output will decrease. This
causes blood to back up into the LA and into the pulmonary circulation. The backflow of
blood into the pulmonary vasculature can cause pulmonary edema, and acute, lifethreatening disorder that must be managed in an acute care setting and may require
advanced resuscitation techniques and aggressive medication and airway management.
This acute on chronic exacerbation of HFpEF accounts for the majority of hospital
admissions in patients 65 years of age or older (Farris et al., 2017).
In an outpatient setting, the symptoms associated with HFpEF can cause a reduction in
the quality of life for the patient without proper management through diet changes,
lifestyle changes, and medication (Harper et al., 2018).
Diuretics are the hallmark of HFpEF management because of their ability to reduce
preload. If there is less preload, the heart may not struggle to pump an increased
volume of blood forward, reducing the instances of acute on chronic exacerbations
(Harper et al., 2018).
Management can also include medications such as beta blockers, which contribute to a
decrease in afterload that can augment the cardiac output, and ACE inhibitors, which
can prevent remodeling of the heart muscle (Harper et al., 2017).

Figure 3. An illustration of heart
muscle hypertrophy in HFpEF
("Diastolic Heart Failure," 2010).
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Significance of Pathophysiology
•

Risk Factors
•
Age > 70
•
Female sex
•
Obesity
•
Hypertension
•
Tobacco use
•
Diabetes mellitus
•
Coronary artery disease
•
Valvular heart disease
•
Atrial fibrillation
(Gazewood & Turner, 2013)

In normal physiology, the heart achieves optimal cardiac output through the
augmentation of stroke volume and heart rate. Myocardial contractility, the FrankStarling law of stretch, and afterload related to ventricular-atrial coupling a determine
stroke volume. Diastole affects these components. In beginning diastole, elastic recoil
relating to the Frank-Starling law and active myocardial relaxation creates a negative
pressure gradient, allowing passive filling of the LV, which accounts for 80% of
ventricular filling. Following this passive filling, the LA contraction, or “kick,” causes the
remainder of ventricular filling. When the ventricle reaches its maximum fill capacity,
contraction begins, beginning systole and ejecting blood from the heart. Diastole is an
active process, meaning it requires energy in the form of ATP. Diastole is the process of
the LV filling from the LA through the mitral valve. It is affected by plasma volume,
passive elasticity, and active relaxation of the LV, and the volume and pressure
received from the LA (Farris et al., 2017).
HFpEF has two significant components: alteration of active ventricular relaxation and
myocardial stiffness.
HFpEF impairs the active relaxation of the LV due to reduced cardiac myocyte ATP
production related to the dysfunction of the mitochondria. A decrease in nitrous oxide
(NO) production, an increase in reactive oxygen species, dysfunction of the
endothelium, and ischemia of the microvasculature causes the dysfunction of the
mitochondria. Because of the decrease in ATP production, the cardiomyocytes are
unable to uptake calcium into the sarcoplasmic reticulum appropriately, which
prevents calcium from unbinding to troponin. This calcium mismanagement leaves the
myofilaments unable to uncouple, preventing active relaxation (Farris et al., 2017).
The myocardium becomes stiff in HFpEF due to sarcomere dysfunction and an increase
in extracellular matrix proteins. In a non-diseased resting heart, the action of titin
protein located in the sarcomeres mediates ventricular stiffness and tension. Titin
works as a bidirectional spring and plays a part in early diastolic passive recoil. In
HFpEF, the titin protein does not phosphorylate normally and causes an increase in
resting myocardial stiffness. Excessive extracellular matrix protein production causes
fibrosis and myocardial stiffness in HFpEF by binding to the collagen matrix,
cardiomyocytes, and fibroblasts (Farris et al., 2017).
Because of the impaired relaxation and myocardial stiffness associated with HFpEF, the
heart must work harder to achieve the same ejection fraction (EF). In order to maintain
the necessary EF, the cardiomyocytes may hypertrophy, causing enlargement of the
heart. This enlargement can decrease stroke volume due to reduced available filling
space while not affecting contractility. The enlargement of the cardiac muscle
maintains the ejection fraction, which is stroke volume divided by end-diastolic
volume, or the volume in the heart after ventricular filling has occurred before the
start of systole. Because the pathophysiology of HFpEF causes a reduction of both
stroke volume and end-diastolic volume, the EF is preserved, remaining > 50% (Farris
et al., 2017).

Figure 2. Biological phenotypes in HFpEF (Lewis et al., 2017).

